Telix Pharmaceuticals (NASDAQ:TLX) Stock Rating Upgraded by Wall Street Zen

Telix Pharmaceuticals (NASDAQ:TLX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other research analysts also recently weighed in on the company. Citigroup upped their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Telix Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $21.13.

Telix Pharmaceuticals Stock Performance

Shares of Telix Pharmaceuticals stock opened at $7.52 on Friday. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $20.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The business has a 50-day moving average price of $7.30 and a 200 day moving average price of $8.93.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The business had revenue of $414.02 million during the quarter, compared to the consensus estimate of $421.50 million. On average, analysts predict that Telix Pharmaceuticals will post 0.24 EPS for the current fiscal year.

Institutional Trading of Telix Pharmaceuticals

Several large investors have recently made changes to their positions in TLX. Rhumbline Advisers raised its stake in Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the last quarter. XTX Topco Ltd acquired a new stake in Telix Pharmaceuticals during the 4th quarter worth $89,000. OLD Mission Capital LLC purchased a new stake in shares of Telix Pharmaceuticals during the fourth quarter worth $111,000. Vident Advisory LLC purchased a new stake in shares of Telix Pharmaceuticals during the fourth quarter worth $204,000. Finally, IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.